A Review of the Assessment of Antidepressant-Induced Sexual Dysfunction used In Randomized, Controlled Clinical Trials

Abstract

Background: Sexual dysfunction is a well-known side effect of many antidepressants. Obtaining accurate data on sexual dysfunction from clinical trials is difficult because of methodological problems. This paper reviews the assessment and reporting of sexual dysfunction in clinical trials.

Methods: 79 randomized double-blind studies comparing efficacy and tolerability of new antidepressants in major depressive disorder were included. Papers were searched for the methodology of adverse event assessment and for any information on treatment-emergent sexual dysfunction.

Results: 74.7% of the reviewed studies relied on spontaneous reports, 17.7% on non-specific side-effect checklists and only 7.6% on specific assessment instruments. 31.6% of the reviewed studies reported sexual dysfunction as a side effect of antidepressant treatment. Detailed information on the kind of sexual dysfunction based on DSM-IV terminology was provided by only 10.1% of the papers. More recent studies published in 2000 or later reported sexual dysfunction more often (48.6%) than studies published before the year 2000 (18.2%).

Discussion: The specific assessment of sexual dysfunction should be adopted as a part of the safety and tolerability assessment in clinical trials. Future research is needed to elaborate the advantages and disadvantages of the available instruments for the assessment of sexual dysfunction.

References

• 1 Baldwin DS. Sexual dysfunction associated with antidepressant drugs.  Expert Opin Drug Saf. 2004;  3 457-470
• 2 Balon R. The effects of antidepressants on human sexuality: Diagnosis and management update 2004.  Primary Psychiatry. 2004;  11 58-66
• 3 Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H. et al . Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.  J Clin Psychopharmacol. 2003;  23 358-364
• 4 Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France.  Curr Med Res Opin. 2003;  19 114-124
• 5 Clayton AH, Owens JE, MacGarvey EL. Assessment of paroxetine induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire.  Psychopharmacol Bull. 1995;  31 397-413
• 6 Clayton AH, MacGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability and validity.  Psychopharmacol Bull. 1997;  33 731-745
• 7 Cohen S, Kühn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermundt M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ. Sexual impairment in psychiatric inpatients: focus on depression.  Pharmacopsychiatry. 2007;  40 58-63
• 8 Cunningham LA, Venlafaxine XR. 208 Study Group . Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.  Ann Clin Psychiatry. 1997;  9 157-164
• 9 Demyttenaere K, Fruyt J De, Sienaert P. Psychotropics and sexuality.  Int Clin Psychopharmacol. 1998;  13 ((Suppl 6)) 35-41
• 10 Derogatis LR, Maelisaratos N. The DSFI: a multidimensional measure of sexual functioning.  J Sex Marital Ther. 1979;  5 244-281
• 11 Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.  J Clin Psychiatry. 1996;  57 ((Suppl 2)) 53-62
• 12 Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review.  J Clin Psychiatry. 2001;  62 ((Suppl 3)) 22-34
• 13 Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.  Pharmacopsychiatry. 2006;  39 66-75
• 14 Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN. et al . Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.  Biol Psychiatry. 2003;  54 806-817
• 15 Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.  J Clin Psychiatry. 2002;  63 225-231
• 16 Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.  J Clin Psychopharmacol. 2004;  24 389-399
• 17 Haberfellner EM. Role of receptor binding profiles in antidepressant induced sexual dysfunction.  J Clin Psychiatry. 2002;  63 168
• 18 Haberfellner EM, Rittmannsberger H. Spontanous remission of SSRI-induced orgasm delay.  Pharmacopsychiatry. 2004;  37 127-130
• 19 Harrison WM, Rabkin JG, Ehrhardt AA, Stewart JW. et al . Effects of antidepressant medication on sexual function: A controlled study.  J Clin Psychopharmacol. 1986;  6 144-149
• 20 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiat. 2006;  39 47-51
• 21 Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression.  J Affect Disord. 1999;  56 201-208
• 22 Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.  J Clin Psychiatry. 2000;  61 276-281
• 23 Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire.  Psychother Psychosom. 2001;  70 221-225
• 24 Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.  J Clin Psychiatry. 2005;  66 100-106
• 25 Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management.  J Psychopharmacol. 1997;  11 72-82
• 26 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU-side effect rating scale.  Acta Psychiatr Scand. 1987;  76 ((Suppl 334)) 1-100
• 27 MacGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, MacKnight KM. et al . The Arizona Sexual Experience Scale (ASEX): reliability and validity.  J Sex Marital Ther. 2000;  26 25-40
• 28 Mehtonen OP, Sogaard J, Roponen P, Behnke K. Venlafaxine 631 Study Group . Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder.  J Clin Psychiatry. 2000;  61 95-100
• 29 Modell JG, Katholi CR, Modell JD, Palma RL De. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.  Clin Pharmacol Ther. 1997;  61 476-487
• 30 Montejo-González AL, Llorca G, Izquirdo JA, Ledesma A, Bousono M, Calcedo A. et al . SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and desriptive clinical study of 344 patients.  J Sex Marital Ther. 1997;  23 176-194
• 31 Montejo AL, Llorca G, Izquirdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients.  J Clin Psychiatry. 2001;  62 ((Suppl 3)) 10-21
• 32 Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction.  J Affect Disord. 2002;  69 119-140
• 33 Muller MJ, Ruof J, Graf-Morgenstern M, Porst H, Benkert O. Quality of partnership in patients with erectile dysfunction after sildenafil treatment.  Pharmacopsychiatry. 2001;  34 91-95
• 34 Musa MN, Staneluis JM. Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials.  J Clin Psychiatry. 2000;  61 874
• 35 Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research.  J Clin Psychopharmacol. 1992;  12 3-10
• 36 Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review.  J Clin Psychopharmacol. 1999;  19 67-85
• 37 Rothschild AJ. Sexual side effects of antidepressants.  J Clin Psychiatry. 2000;  61 ((Suppl 11)) 28-36
• 38 Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomized controlled trials.  J Affect Disord. 2005;  88 241-254
• 39 Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.  Can J Psychiatry. 2002;  47 174-180
• 40 Versiani M, Maehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.  J Clin Psychiatry. 1999;  60 400-406
• 41 Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.  J Clin Psychopharmacol. 2002;  20 28-34
• 42 Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ. Comparative Efficacy Antidepressants Study Group . Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.  CNS Drugs. 2005;  19 137-146
• 43 Wade A, Crawford GM, Angus M, Wilson R, Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.  Int Clin Psychopharmacol. 2003;  18 133-141
• 44 Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR. et al . Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.  J Clin Psychiatry. 1993;  54 459-465
• 45 Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction.  Acta Psychiatr Scand. 2006;  114 384-397
• 46 Williams VSL, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries. A cross-sectional patient survey.  J Clin Psychiatry. 2006;  67 204-210
• 47 Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory.  Psychopharmacol Bull. 1997;  33 755-760
• 48 Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RM, Kornstein SG, Ninan PT. et al . Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.  J Clin Psychiatry. 2002;  63 709-716

Correspondence